Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development

This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.

Direct Link:

https://canberra-ip.technologypublisher.com/tech/Immunogenic_Hepatitis_E_Viru s_Polypeptides_for_Vaccine_and_Diagnostics_Development